ARTICLE | Company News
Less than two weeks after stepping down as CEO of Agios Pharmaceuticals Inc. (NASDAQ:AGIO), David Schenkein has joined GV as general partner. Schenkein, who will remain executive chairman of Agios, will co-lead the firm’s life science investment team.
A veteran of Genentech Inc. and Millennium Pharmaceuticals Inc., Schenkein joined Agios in 2009 and guided the cancer metabolism drug Idhifa enasidenib from concept to approval in just over eight years. Idhifa is approved to treat adults with relapsed or refractory acute myelogenous leukemia (AML) who harbor the isocitrate dehydrogenase 2 (IDH2) mutation; a second Agios AML drug, Tibsovo ivosidenib, reached the market last year (see "Agios' Acceleration")...